Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05506566
Overview
As an emerging molecule targeting FAP, 68Ga-FAP-CHX is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAP-CHX in patients with various types of cancer and compared them with the results of 68Ga-FAPI-04 or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAP-CHX.
Sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Phase 1/2
Contacts
Weibing Miao, MD
miaoweibing@126.com
86-0591-87981618
Jie Zang, MD
15901495106@163.com
15901495106
ClinicalTrials.gov
NCT05506566Drug / Compound
Help us improve your experience